Positive phase 3 data for Sanofi’s Dupixent
Research showed significant improvements in signs and symptoms of prurigo nodularis
Read MoreResearch showed significant improvements in signs and symptoms of prurigo nodularis
Read MoreYou can still submit your entry before the imminent 16 September 2022 deadline – but hurry!
Read MoreGet started on your entry for these prestigious awards now – the deadline is 16 September 2022
Read MoreEntering the singles categories is simple, quick and free, but hurry – the deadline is 16 September 2022
Read MoreCollaboration involves the marketing and distribution of PreHevbri across Europe
Read More




PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
